Doseology Sciences (MOOD) AI Stock Analysis

Doseology Sciences

(CNQX:MOOD)

Select Model

Rating:45Neutral

Price Target:CAD 0.21▲(147.06% Upside)

Action:reiterated

Date:07/24/26

The score is held back primarily by weak financial performance, including falling revenue, widening losses, and ongoing cash burn. Technical indicators also point to poor momentum, while valuation offers little support because the company remains unprofitable. The clean balance sheet prevents the score from being lower.

Positive Factors

Debt-free balance sheetA near-zero debt position and equity cushion materially reduce leverage risk and give the company more financing flexibility over the medium term. This durable strength lowers default risk and supports strategic options (M&A, licensing, or capital raises) while losses persist.

Negative Factors

Persistent operating lossesLarge ongoing operating deficits relative to revenue show the business has not scaled to cover fixed costs. Persistent losses will continue to erode equity, limit reinvestment capacity, and force reliance on external capital unless meaningful margin improvements are achieved.

Doseology Sciences (MOOD) vs. iShares MSCI Canada ETF (EWC)

Market Cap: CAD 680.99K
Dividend Yield: ―
Average Volume (3M): 4,623
Price to Earnings (P/E): -0.6
Beta (1Y): -2.75
Revenue Growth: 73.76%
EPS Growth: -108.30%
Country: Canada
Employees: 5
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Pharmaceuticals

Doseology Sciences Business Overview & Revenue Model

Company Description

Doseology Sciences Inc., through its subsidiary, Dose Labs Inc., engages in the research, development, and sale of functional mushroom products with a focus on mental health research in Canada. The company also offers medicinal mushroom products, inc...

How the Company Makes Money

null

Doseology Sciences Financial Statement Overview

Summary

The balance sheet is the main strength, with growing equity, zero debt, and stable liquidity, but this is offset by a sharp revenue decline, widening losses, and continued cash burn. The overall financial profile is weak but supported by a clean capital structure.

Income Statement

25Negative

Balance Sheet

75Positive

Cash Flow

45Neutral

Financial statement breakdown
Breakdown	TTM	Sep 2025	Sep 2024	Sep 2023	Sep 2022	Jun 2021
Income Statement
Total Revenue	20.29K	42.56K	98.52K	43.09K	16.05K	0
Gross Profit	9,978	18.89K	72.09K	41.29K	-148.38K	-92.83K
EBITDA	-389.53K	-471.61K	-319.48K	-1.78M	-1.72M	-1.47M
Net Income	-370.38K	-447.79K	-339.85K	-1.78M	-1.94M	-1.63M
Balance Sheet
Total Assets	1.49M	1.49M	1.10M	1.40M	3.87M	5.99M
Cash, Cash Equivalents and Short-Term Investments	1.43M	1.43M	1.06M	1.30M	1.87M	3.73M
Total Debt	0	0	0	50.27K	746.10K	687.54K
Total Liabilities	94.11K	94.11K	82.49K	99.19K	871.51K	3.41M
Stockholders Equity	1.40M	1.40M	1.02M	1.30M	3.00M	2.58M
Cash Flow
Free Cash Flow	-230.84K	-342.24K	-235.12K	-481.05K	-1.72M	-2.54M
Operating Cash Flow	-230.85K	-342.24K	-235.12K	-481.05K	-1.71M	-2.37M
Investing Cash Flow	0	0	0	0	-7,875	-26.05K
Financing Cash Flow	711.68K	711.68K	-6,138	-91.88K	-140.08K	5.79M

Doseology Sciences Technical Analysis

Technical Analysis SentimentNegative

Last Price0.09

Price Trends

50DMA0.15Negative

100DMA0.18Negative

200DMA0.39Negative

Market Momentum

MACD-0.02Positive

RSI32.59Neutral

STOCH-4.76Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MOOD, the sentiment is Negative. The current price of 0.09 is below the 20-day moving average (MA) of 0.12, below the 50-day MA of 0.15, and below the 200-day MA of 0.39, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 32.59 is Neutral, neither overbought nor oversold. The STOCH value of -4.76 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:MOOD.

Doseology Sciences Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

TSE:MOOD against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TSE:MOOD	45Neutral	CAD 680.99K	-0.57	-85.01%	―	73.76%	-108.30%
TSE:DOSE	38Underperform	CAD 14.33M	-4.41	46.54%	―	4.30%	38.28%

* Healthcare Sector Average

Performance Comparison

TSE:MOOD and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TSE:MOOD	Doseology Sciences, Inc.	0.09	-0.26	-75.71%
TSE:DOSE	Rapid Dose Therapeutics Corp	0.10	-0.06	-34.38%
TSE:MYND	Mynd Life Sciences Inc	0.07	0.00	0.00%
TSE:IBO	Universal Ibogaine Inc	0.01	0.00	0.00%
TSE:MBIO	Mindbio Therapeutics Corp.	0.10	-1.90	-94.75%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Jul 24, 2026

Doseology Sciences AI Stock Analysis